Accession Number : AD1047610

Title :   EF5 PET of Tumor Hypoxia: A Predictive Imaging Biomarker of Response to Stereotactic Ablative Radiotherapy (SABR) for Early Lung Cancer

Descriptive Note : Technical Report,15 Aug 2012,14 Aug 2017

Corporate Author : The Leland Stanford Junior University Stanford United States

Personal Author(s) : Loo, Billy Jr W

Full Text :

Report Date : 01 Nov 2017

Pagination or Media Count : 16

Abstract : Stereotactic ablative radiotherapy (SABR) has become a new standard of care for early stage lung cancer in patients who are not candidates for surgery because of excessive surgical risk, and will be an important treatment option for a growing segment of patients with lung cancer. This is particularly true as lung cancer screening efforts are expected to diagnose a greater proportion of lung cancers at earlier stages, yet the aging of the population will lead to a greater proportion of patients having comorbidities that increase surgical risk. Tumor hypoxia is a major known mechanism of radiation resistance and is especially expected to affect very short courses of radiation as in SABR. Imaging using a third-generation hypoxia PET agent, 18F-EF5,is a promising approach for noninvasive hypoxia measurement that needs to be validated in the clinical setting.

Descriptors :   lung cancer , RADIOTHERAPY , Positron emission tomography , hypoxia , metastasis

Subject Categories : Medicine and Medical Research

Distribution Statement : APPROVED FOR PUBLIC RELEASE